SomnoMed Limited

SomnoMed Limited

SOMNF
SomnoMed LimitedUS flagOther OTC
0.45
USD
-NaN
- -
98.90MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2026 Y
Revenue per Share
0.27
0.38
0.46
0.58
0.58
0.73
0.64
0.67
0.59
0.68
0.79
0.76
- -
Basic EPS, GAAP
0.01
0.01
0.01
- -
-0.04
-0.1
-0.18
-0.01
-0.01
-0.04
-0.08
-0.1
- -
Free Cash Flow per Basic Share
- -
-0.02
-0.02
- -
-0.06
-0.02
-0.02
-0.03
-0.04
-0.08
-0.06
-0.04
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.16
0.19
0.28
0.42
0.4
0.42
0.23
0.35
0.3
0.26
0.23
0.22
0.22
Tangible Book Value per Share
0.07
0.02
0.14
0.34
0.33
0.34
0.14
0.27
0.22
0.12
0.05
0.12
0.11
Basic Weighted Avg Shares
68
68
75
77
85
88
91
85
106
106
106
121
- -
Sales/Revenue/Turnover
18
26
34
44
49
64
59
57
63
73
84
92
115
Operating Margin (%)
1.11
1.22
0.12
0.15
-7.57
-13.94
1.56
-1.64
-1.36
-5.69
-4.87
-9.09
0.85
Depreciation Expense
1
1
1
1
1
2
1
3
4
4
5
6
5
Net Income, GAAP
1
- -
1
- -
-3
-9
-16
-1
-1
-4
-8
-12
-3
Effective Tax Rate (%)
- -
6.74
23.53
86.31
- -
- -
106.49
158.68
- -
- -
- -
- -
- -
Profit Margin (%)
3.18
1.57
1.73
0.37
-6.78
-13.55
-27.91
-1.95
-1.9
-6.11
-9.57
-13.36
-2.31
Working Capital
5
6
14
22
20
20
3
24
18
3
11
19
16
LT Debt
- -
- -
- -
- -
- -
1
- -
8
7
5
21
4
3
Total Equity
12
13
23
35
35
35
20
37
32
28
25
46
47
Return on Invested Capital (%)
- -
2.32
0.17
0.03
- -
- -
-0.18
1.36
- -
- -
- -
- -
- -
Return on Capital (%)
- -
4.92
3.73
0.92
- -
- -
-51.93
-3.06
- -
- -
- -
- -
- -
Return on Common Equity (%)
5.99
3.4
3.33
0.57
-9.38
-23.13
-56.03
-3.9
-3.45
-14.8
-30.59
-34.77
-5.68

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.21%
10.46%
3.24%
Free Cash Flow
-551.52%
33.08%
7.38%
Net Income, GAAP
-171.01%
66.71%
-78.35%
Sales/Revenue/Turnover
13.37%
14.99%
24.97%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
92
2026
- -
- -
- -
- -
115

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-0.1
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Karen Borg
Full Time Employees
461
Sector
Healthcare
Industry
Medical - Devices
Address
20 Clarke Street Crows Nest NSW Australia 2065
IPO Date
Oct 15, 2010
Business
SomnoMed Limited operates as a medical technology enterprise, delivering advanced oral solutions for sleep-related breathing conditions across multiple international markets, including Europe, North America, and the Asia Pacific region. The company's primary offerings include its clinically proven SomnoDent line of custom-fitted oral appliances, designed to effectively manage obstructive sleep apnea by gently repositioning the jaw. Complementary products consist of the SomnoBrux dental guard for addressing teeth grinding, the SomMorning Repositioner to aid mandibular return, and SomTabs for device cleaning. Further enhancing its portfolio, SomnoMed is actively advancing its Rest Assure platform, an innovative tech-enabled oral appliance integrating biosensor technology for objective treatment data. Established in 2004, the firm maintains its corporate headquarters in Sydney, Australia.

Company News

  • SomnoMed Limited (SOMNF) Q4 2026 Earnings Call Transcript

  • SomnoMed Limited (SOMNF) Q2 2026 Earnings Call Transcript